News

CAR T-cell therapy could be used to treat acute myeloid leukaemia (AML)- with the aid of CRISPR gene editing, a US study has revealed. Researchers at the University of Pennsylvania's Abramson Cancer Center used the therapy to target the protein CD33, which is expressed on healthy and cancerous cells, in animal models of AML. They used genome editing to remove CD33 from healthy blood-forming stem cells. This left the cancerous cells as the only targets left for the CD33 hunter cells to attack. The findings are published in the latest edition of Cell. The innovation follows previous research by Penn scientists, who developed CAR T cell therapy to treat AML. The current approach involves targeting the myeloid marker CD33,...